Messenger RNA encoding the /33-adrenergic receptor is present in human white and brown adipose tissue (1) .
Because /33-adrenoceptor agonists (2) that stimulate lipolysis in white adipose tissue (WAT) and activate brown adipose tissue (BAT) could emerge as effective drugs for the treatment of obesity and diabetes in obese persons, the study and development of such substances are being actively pursued (3) (4) (5) . The /93-agonists that have been developed to date have residual side effects at ß\-and /32-adrenergic receptors in humans (6) . We now described the effects of the /33-adrenoceptor agonist CL 316,243 (7) , which is superior to conventional drugs in terms of/33-receptor specificity (relative selectivities of 0, 1 and 100 000 for ßx-, ß2-and /33-receptors, respec¬ tively), on obesity induced by monosodium L-glutamate (MSG) in mice (8) (9) (10) . Obesity was induced in 30 male ICR mice (Charles River Japan, Tokyo, Japan) by daily subcutaneous injection with MSG (2 g/kg body mass) (Wako Pure Chemical Industries, Tokyo, Japan) immediately after birth for five consecutive days (8) (9) (10) (2) (3) (4) (5) and Zucker fa/fa rats (18) . The effects of CL 316,243 were apparent at one-tenth to onetwentieth of the dose of the /33-agonist BRL 26830A shown to be effective in our previous studies (11, 19) .
With regard to the increase in the RMR induced by CL 316,243, it is unclear whether this compound has any effect on protein metabolism. Studies in rats with other ßi-agonists have shown that BRL 26830A has no effect on muscle mass, whereas BRL 35135 increases soleus muscle mass but has no effect on the mass of gastrocnemius or plantaris muscles (3) . We have also observed previously (20) 
